Stock / equity
CCJ Cameco Corporation Common Stock
- Security
- Equity
- Members of Congress
- 2
- Latest trade on record
- January 9, 2026
CCJ (Cameco Corporation Common Stock) has 0 disclosed insider transactions from 0 insiders in the last 12 months (0 open-market buys, 0 sales, about $0 at reported prices) and 5 congressional trades from 2 members of Congress. The most recent disclosure was filed August 5, 2026.
Share price
Price and chart by TradingView for Cameco Corporation Common Stock. US share prices here are delayed, not real-time. The trade records on this page come from government filings, not from this chart.
CCJ in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
1 person accounts for the disclosed buying and selling in CCJ over the last 12 months; the most active is Rep. Gilbert Ray Cisneros, Jr. with $45K.
Members of Congress trading CCJ
Members whose periodic transaction reports name this ticker. Amounts are the sums of the ranges as filed.
| Member | Seat | Trades | Bought | Sold | Range as filed | Latest |
|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Representative (CA, District 31), Democrat | 4 | 2 | 2 | $4,004–$60K | January 9, 2026 |
| Tommy Tuberville | Senator (AL), Republican | 1 | 1 | 0 | $1,001–$15K | May 7, 2024 |
Insider transactions
No Form 4 transactions for this ticker in the tracked window yet.
Congressional trades
| Filer | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Tommy Tuberville | Buy | May 7, 2024 | August 5, 2026 | — | — | — | $1,001–$15K | jointderivative | Senate PTR ↗ | |
| Gilbert Ray Cisneros, Jr. | Sell | January 9, 2026 | February 13, 2026 | 35d | — | — | $1,001–$15K | House PTR ↗ | ||
| Gilbert Ray Cisneros, Jr. | Sell | December 24, 2025 | January 12, 2026 | 19d | — | — | $1,001–$15K | House PTR ↗ | ||
| Gilbert Ray Cisneros, Jr. | Buy | November 18, 2025 | December 15, 2025 | 27d | — | — | $1,001–$15K | House PTR ↗ | ||
| Gilbert Ray Cisneros, Jr. | Buy | October 17, 2025 | November 18, 2025 | 32d | — | — | $1,001–$15K | House PTR ↗ |
Related stocks
Tickers traded by the same people who traded CCJ, by number of filers in common. It shows overlap in public filings and nothing else.
- NFLX Netflix, Inc. - Common Stock 2 filers in common
- ADBE Adobe Inc. - Common Stock 2 filers in common
- LLY Eli Lilly and Company Common Stock 2 filers in common
- ACN Accenture plc Class A Ordinary Shares 2 filers in common
- CVX Chevron Corporation Common Stock 2 filers in common
- GOOGL Alphabet Inc. - Class A Common Stock 2 filers in common
- PG Procter & Gamble Company 2 filers in common
- HON Honeywell International Inc. 2 filers in common
Guides for this page
- How to read a congressional trade report Owner tells you whose asset it was: the member, the spouse, a dependent child, or held jointly.
- Why congressional trade amounts are ranges There are ten ranges; the lowest is $1,001–$15,000 and the highest is over $50,000,000.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| House Clerk, periodic transaction reports | 4 | 4 | November 18, 2025 | February 13, 2026 | House Clerk search |
| Senate eFD, periodic transaction reports | 1 | 1 | August 5, 2026 | August 5, 2026 | Senate eFD search |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insider rows are Form 4 filings for this issuer from SEC EDGAR; congressional rows are periodic transaction reports parsed from the House Clerk and the Senate eFD. Values use the reported price for Form 4 and the disclosed range for Congress. See methodology and corrections.
Not investment advice. Disclosures are shown as filed and may lag the trade or be amended. No recommendation is made or implied.